Ignite Creation Date:
2024-05-06 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06203145
Status:
RECRUITING
Last Update Posted:
2024-01-12
First Post:
2023-12-21
Brief Title:
A Clinical Study on the Whole-course Management BCD-KPD-AutoHSCT Scheme for Patients With RIMM
Sponsor:
Peking University First Hospital
Organization:
Peking University First Hospital
Study Overview
Official Title:
A Clinical Study on the Whole-course Management BCD-KPD-AutoHSCT Scheme for Patients With Multiple Myeloma and Kidney Injury
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multiple myeloma MM is still an incurable hematological tumor and renal involvement is the main factor of poor prognosis The recovery of renal function can partially reverse its poor outcome Although the 5-year survival rate of MM patients has significantly improved after entering the era of new drugs patients with severe renal insufficiency still have a high early mortalityThe purpose of this study is to investigate whether early intensive chemotherapy can reverse the proportion of renal insufficiency is to investigate the treatment effect of RIMM patients with different renal pathological types and is also to investigate whether autoHSCT can further partially save renal function in RIMM patients
Detailed Description:
For patients with multiple myeloma with renal impairment the same disease stage and the same treatment regimen have different therapeutic effects In the era of new drugs studies have shown that early reduction of the free light chain in serum is the key to reversing renal function The International Myeloma Working Group recommends the following drugs for the treatment of RIMM patients 1 regimens based on proteasome inhibitors 2 regimens based on immunomodulators Here we explore a clinical study on the Whole-course Management BCD-KPD-AutoHSCT scheme for patients with RIMM
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None